<DOC>
	<DOCNO>NCT00113724</DOCNO>
	<brief_summary>Tapestry Pharmaceuticals , Inc. develop novel taxane analog , TPI 287 . TPI 287 synthetically manufacture naturally occur taxanes extract yew start material . The synthesis involve modification taxane side chain overcome multidrug resistance achieve mutant tubulin binding . This study multi-center , dose escalation , sequential group , phase I study evaluate intravenous administration TPI 287 , novel third generation taxane .</brief_summary>
	<brief_title>Study TPI 287 Patients With Advanced Malignancies</brief_title>
	<detailed_description>The primary objective study determine maximum tolerate dose TPI 287 phase II clinical trial . The secondary objective study : - To determine safety TPI 287 - To determine antitumor activity TPI 287 - To determine pharmacokinetic profile TPI 287 - To determine pharmacodynamic profile TPI 287</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Histological cytological evidence malignancy Patients must either : advanced solid tumor recur progress follow standard therapy , Hodgkin 's nonHodgkin 's lymphoma recur progress follow standard therapy , previous bone marrow transplant , eligible bone marrow transplant . Failed least one previous therapeutic regimen either longer candidate standard therapy , standard therapy available , choose pursue standard therapy . Ambulatory ECOG 0 1 , life expectancy &gt; 3 month . Judged investigator initiative mean compliant protocol within geographical proximity make require study visit . Have ability read , understand provide write informed consent initiation study related procedure legal representative perform function . If female , must negative pregnancy test within 21 day start treatment . Agree use effective method contraception study 90 day follow last dose medication . Patients prior radiation therapy brain metastasis primary brain tumor acceptable . Prior radiation therapy chemotherapy within 4 week ( 6 week prior nitrosoureas mitomycin ) Another active medical condition ( ) organ disease ( ) may either compromise patient safety interfere safety and/or outcome evaluation study drug . While exclusion limit follow abnormality , follow laboratory abnormality present , patient exclude : WBC &lt; 3000/uL ; Absolute neutrophil count &lt; 1500/uL ; Platelets &lt; 100,000/uL ; Total bilirubin &gt; 1.5 x upper limit normal ; ALT AST &gt; 3 x upper limit normal liver metastasis &gt; 5 upper limit normal presence liver metastases ; Serum creatinine &gt; 1.5 x upper limit normal ; INR &gt; 2.0 . Patient clinically significant cardiac comorbidities pulmonary impairment Patient physician plan concomitant chemotherapy , radiation therapy , hormonal and/or biological treatment cancer include immunotherapy study . Of note , therapy LHRH prostate cancer acceptable . Patient treat investigational drug , investigational biologic , investigational therapeutic device within 30 day initiate study treatment . Tumor appear involve major artery vein . Prior concurrent significant CNS disease include stroke , except primary secondary malignancy . Less 4 week since prior major surgery Known positive HIV , Hepatitis B C Concurrent chronic use aspirin ( 325 mg/day ) Concurrent recent ( within 1 month ) use thrombolytic agent , fulldose anticoagulant ( except maintain patency preexisting , permanent indwell IV catheter ) Of note , therapy lowmolecular weight heparin acceptable long INR &lt; 2.0 . Uncontrolled hypertension Grade IIIV peripheral vascular disease within past year Prior allergic reaction compound similar chemical biologic composition TPI 287 , paclitaxel taxotere , CremophorELP , study agent Significant traumatic injury within past 4 week Ongoing active infection require parenteral antibiotic fever &gt; 38.1Â°C within 3 day first schedule day dose Other concurrent uncontrolled illness may interfere ability patient participate trial Patients inpatient Grade IIIV peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>taxane</keyword>
	<keyword>multi-drug resistance</keyword>
	<keyword>mutant tubulin binding</keyword>
	<keyword>Advanced malignancy</keyword>
	<keyword>Hodgkin 's Non-Hodgkin 's Lymphoma</keyword>
</DOC>